Recently, RoboCT's UGO serie rehab exoskeletons have been approved for CE certification as medical devices after passing the CSA (Canadian Standards Association) group safety test, further enhancing the competitiveness in the international markets. After obtaining CE certification, RoboCT Technology's rehab exoskeleton products will be able to successfully enter the EU market and provide rehabilitation services to users in more countries and regions.

The safety test certification award ceremony was attended by RoboCT Technology and CSA Group executives as well as the project manager. RoboCT Technology's UGO 220 exoskeleton successfully obtained the first compliance certificate for lower-limb exoskeleton in mainland China.

RoboCT's rehab exoskeleton have passed the CSA Group's safety test certification means that the products have achieved international standards in terms of safety and reliability. Subsequently, passing CE certification will strongly support the RoboCT's expansion into the EU market, while also helping to increase the brand's popularity and worldwide influence.

The UGO serie rehab exoskeleton is suitable for people with lower-limb motor dysfunction caused by spinal cord injury, stroke, lower-limb muscle weakness, or other neurological diseases. It is mainly used in rehabilitation departments of hospitals and medical institutions to help lower-limb rehabilitation patients to walk. The product has been certified in accordance with the latest industry standards, including product safety, EMC electromagnetic compatibility, medical software, usability and robotics performance standards (IEC80601-2-78), and the international version fully meets the international market access standard requirements in terms of technology.

With the aggravation of the global aging problem and the increase in the number of patients with neurological diseases, the demand for rehabilitation exoskeletons is growing. With the excellent performance and international certification of the UGO rehab exoskeleton, it is expected to take a place in the global market. RoboCT Technology will also continue to increase investment in R&D, continuously optimize product functions, and explore new application scenarios to meet broader market needs, and bring hope and comfort to more patients.